Wire · operational-macro
Shionogi is buying rare disease biotech IntraBio for $2 billion
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
Shionogi is acquiring Austin-based rare disease biotech IntraBio for $2 billion, gaining global rights to Aqneursa, a drug approved in the U.S. and E.U. for treating neurological manifestations of Niemann-Pick disease type C and Ataxia-Telangiectasia, along with additional neurodegenerative disease programs.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 5 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
Biotech founders in rare diseases should note major players like Shionogi are accelerating market consolidation through buying approved drugs and pipelines. Your best exit may now be via acquisition if you hold assets in neurodegenerative or rare disease therapeutics.
◆ Coverage
5 sources · first reported 5 Oct 2026 · latest 6 Oct 2026
◆ Related on Wire
◆ Topics